Utilization of genetic biomarkers testing and its associated factors in advanced colorectal cancer patients in China: a nationwide multicenter clinical epidemiological study
文献类型：期刊论文
| 作者 | Zhang, Xi20; Lian, Xue-Mei19; Gu, Xiao-Fen18; Liu, Yin17; Feng, Chang-Yan16; Li, Li15; Xu, Hui-Fang17; Du, Jing-Chang14; Zhao, Yu-Qian13; Ma, Li12 |
| 刊名 | ANNALS OF TRANSLATIONAL MEDICINE
 |
| 出版日期 | 2022-03-16 |
| ISSN号 | 2305-5839 |
| 关键词 | Colorectal cancer (CRC) biomarker RAS BRAF microsatellite instability (MSI) |
| DOI | 10.21037/atm-22-988 |
| 通讯作者 | Zhang, Shao-Kai(shaokaizhang@126.com) ; Shi, Ji-Hai(sjh@btmc.edu.cn) ; Qiao, You-Lin(qiaoy@cicams.ac.cn) |
| 英文摘要 | Background: Biomarkers are a key tool in early detection, prognostication, survival, and predicting treatment response of colorectal cancer (CRC). However, little is known about biomarker testing for CRC patients in real-life clinical practice in China. This study aimed to address the usage of biomarker testing and analyze factors related to its acceptance among Chinese patients with advanced CRC. Methods: A multicenter, cross-sectional, hospital-based clinical epidemiology study was conducted from March 2020 to March 2021. Nineteen hospitals were selected in seven geographical regions of China using stratified, multistage, nonrandomized cluster sampling. Data on demographics and clinical characteristics of each eligible CRC patient in stage III or IV diseases were recorded based on the patients' self-reporting and/ or medical records. In addition, information on whether biomarker testing [RAS, BRAF, and microsatellite instability (MSI)] was performed, the results and timing for performing biomarker testing, and the reasons for refusing biomarker testing were also recorded. Univariate and multivariate logistic regression were conducted to explore the potential factors of biomarker testing. Results: A total of 4,526 patients were enrolled in the study, of whom 41.4%, 36.1%, and 28.2% underwent RAS, BRAF, and MSI testing, respectively. RAS, BRAF, and high-level MSI (MSI-high) mutation rates in Chinese patients with advanced CRC were 37.0%, 9.9%, and 8.1%, respectively. The logistic regression analysis revealed that the treating hospital, age at diagnosis, education, family income, tumor site, history of chemotherapy and radiotherapy, and metastases were dependent factors affecting the utilization of biomarker testing in advanced CRC in China (P<0.005). Conclusions: The biomarker testing rate, especially MSI testing, is less prevalent in clinical practice for patients with advanced CRC in China. Our findings may guide the formulation of biomarker testing of CRC strategies in China and other low-income countries. |
| WOS关键词 | BRAF MUTATION ; MICROSATELLITE INSTABILITY ; 1ST-LINE TREATMENT ; POOLED ANALYSIS ; RAS MUTATIONS ; K-RAS ; CETUXIMAB ; SURVIVAL ; CHEMOTHERAPY ; POPULATION |
| 资助项目 | Beijing Love Book Cancer Foundation ; Merck Serono Co., Ltd. |
| WOS研究方向 | Oncology ; Research & Experimental Medicine |
| 语种 | 英语 |
| 出版者 | AME PUBL CO |
| WOS记录号 | WOS:000779715100001 |
| 资助机构 | Beijing Love Book Cancer Foundation ; Merck Serono Co., Ltd. |
| 源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/128689]  |
| 专题 | 中国科学院合肥物质科学研究院 |
| 通讯作者 | Zhang, Shao-Kai; Shi, Ji-Hai; Qiao, You-Lin |
| 作者单位 | 1.Chinese Acad Med Sci & Peking Union Med Coll, Sch Populat Med & Publ Hlth, Ctr Global Hlth, 9 Dongdansantiao, Beijing 100005, Peoples R China 2.Baotou Med Coll, Affiliated Hosp 1, Dept Dermatol, Clin Epidemiol Res Ctr, 41 Linyin Rd, Baotou 014010, Peoples R China 3.Baotou Med Coll, Clin Epidemiol Res Ctr, Dept Publ Hlth & Prevent Med, Baotou, Peoples R China 4.Sun Yat Sen Univ Canc Ctr, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Peoples R China 5.Fining Med Univ, Sch Nursing, Jining, Peoples R China 6.Xinxiang Cent Hosp, Dept Prevent Hlth, Xinxiang, Henan, Peoples R China 7.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Dept Canc Prevent, Canc Hosp, Hangzhou, Peoples R China 8.Gansu Prov Canc Hosp, Dept Publ Hlth, Lanzhou, Peoples R China 9.Guangxi Med Univ, Dept Canc Prevent & Control Off, Affiliated Hosp 1, Nanning, Peoples R China 10.Wuzhou Red Cross Hosp, Dept Gastroenterol, Wuzhou, Peoples R China |
| 推荐引用方式 GB/T 7714 | Zhang, Xi,Lian, Xue-Mei,Gu, Xiao-Fen,et al. Utilization of genetic biomarkers testing and its associated factors in advanced colorectal cancer patients in China: a nationwide multicenter clinical epidemiological study[J]. ANNALS OF TRANSLATIONAL MEDICINE,2022. |
| APA | Zhang, Xi.,Lian, Xue-Mei.,Gu, Xiao-Fen.,Liu, Yin.,Feng, Chang-Yan.,...&Qiao, You-Lin.(2022).Utilization of genetic biomarkers testing and its associated factors in advanced colorectal cancer patients in China: a nationwide multicenter clinical epidemiological study.ANNALS OF TRANSLATIONAL MEDICINE. |
| MLA | Zhang, Xi,et al."Utilization of genetic biomarkers testing and its associated factors in advanced colorectal cancer patients in China: a nationwide multicenter clinical epidemiological study".ANNALS OF TRANSLATIONAL MEDICINE (2022). |
入库方式： OAI收割
来源：合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。